Nuclear Transfer Research - Elaine Fuchs (Rockefeller/HHMI)
The transfer of the nucleus from an adult cell into an enucleated oocyte can generate stem cells that go on to produce healthy mice. While this technology holds promise for regenerative medicine...

By: iBioEducation

See original here:
Nuclear Transfer Research - Elaine Fuchs (Rockefeller/HHMI) - Video

Recommendation and review posted by sam

The University of North Carolina School of Medicine created the Gene Therapy Center in 1996 with the goal of merging molecular genetics research with healthcare delivery. The Gene Therapy Center provides important resources to academic investigators through two core facilities created to support preclinical and clinical gene therapy studies. These facilities, the Vector Core and the Human Applications Laboratories, were created to ensure that investigators would have promising gene vectors available in the quality and quantities needed for preclinical or clinical studies. Research in the laboratory has centered on the molecular biology of adeno-associated virus (AAV) in order to exploit the unique features of this virus to develop an efficient viral vector system for use in human gene therapy. Continued efforts in understanding the mechanism of viral replication and integration for both wild-type and recombinant AAV are being pursued in order to create more efficient gene transfer vectors. The ultimate goal of the Gene Therapy Center is to facilitate the progression and translation of gene therapy research from the laboratory bench into Phase I clinical trials for the treatment of human disease. Click here to learn more about our gene therapy research.

Announcements

February 2013

Symposium: The Nexus of Gene Therapy & Regenerative Medicine

Location: The Old Salem Visitor Center, Winston-Salem, NC

Date: Thursday, February 7, 2013 9AM - 6PM

October 2011

Gene Therapists Celebrate a Decade of Progress

http://www.sciencemag.org/content/334/6052/29.full

Here is the original post:
the Gene Therapy Center - University of North Carolina at Chapel ...

Recommendation and review posted by Bethany Smith

Presentation of Stevens Rehen - Nairobi Cell Biology/Regenerative Medicine Meeting 2013
Cell Biology and Regenerative Meeting, Nairobi, Kenya, 2013. Induced pluripotent stem cells to study brain diseases by Stevens Rehen. National Laboratory for...

By: Stevens Rehen

Read more from the original source:
Presentation of Stevens Rehen - Nairobi Cell Biology/Regenerative Medicine Meeting 2013 - Video

Recommendation and review posted by sam

stem cell therapy treatment for Quadriplegic Cerebral Palsy by dr alok sharma, mumbai, india
improvement seen in just 3 months after stem cell therapy treatment for quadriplegic cerebral palsy by dr alok sharma, mumbai, india. Stem Cell Therapy done ...

By: Neurogen Brain and Spine Institute

View post:
stem cell therapy treatment for Quadriplegic Cerebral Palsy by dr alok sharma, mumbai, india - Video

Recommendation and review posted by Bethany Smith

New Genentech Medicine for Previously Untreated Chronic Lymphocytic Leukemia

At Genentech, our t-shirts represent our stories - about our people, our community, and ultimately about the impact of biotechnology on medicine.

Genentech is committed to ensuring price is not a barrier to access for patients. Learn about our programs.

Physicians can now use our secure online portal to review Sunshine-reportable payments before they are reported to the government.

Search for jobs. Learn more about what is currently available. And then apply for the position at Genentech thats right for you.

Genentech Disappointed with CA Governor's Veto of Patient Access to Biosimilars Bill

Insights on trends, events, and therapeutic advances. Learn more at Genentech-Forum.com.

Ann Lee-Karlon, Ph.D., SVP of Portfolio Management and operations on how teams and decision making influence drug discovery and development.

Our pipeline includes over 30 new molecular entities that address serious unmet medical needs.

Partnering is a relatively new phenomenon for biopharmaceutical companies, but collaboration has been part of Genentechs DNA from the beginning.

View original post here:
Genentech - Official Site

Recommendation and review posted by Bethany Smith

Paringa Livestock Sheep Genetics Overview 2013

By: clearvisionimaging

See the article here:
Paringa Livestock Sheep Genetics Overview 2013 - Video

Recommendation and review posted by Bethany Smith

Advances in SCI Treatment
History and Outlook: Spinal cord injury research Spinal cord injury (SCI) remains one of the most vexing unanswered disorders affecting human kind. While the...

By: UWTV

Read the original post:
Advances in SCI Treatment - Video

Recommendation and review posted by sam

Prof. Sir Ian Wilmut - The Quest for New Therapies by Stem Cell Research
Professor Sir Ian Wilmut, Professor Emeritus at the University of Edinburgh and Chairman of the Scottish Centre for Regenerative Medicine, presents "The Ques...

By: EdinburghUniversity

Continue reading here:
Prof. Sir Ian Wilmut - The Quest for New Therapies by Stem Cell Research - Video

Recommendation and review posted by sam

BACKGROUND:

SCIPIO is a first-in-human, phase 1, randomized, open-label trial of autologous c-kit(+) cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology undergoing coronary artery bypass grafting (CABG). In the present study, we report the surgical aspects and interim cardiac magnetic resonance (CMR) results.

A total of 33 patients (20 CSC-treated and 13 control subjects) met final eligibility criteria and were enrolled in SCIPIO. CSCs were isolated from the right atrial appendage harvested and processed during surgery. Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times. In CSC-treated patients, CMR showed a marked increase in both LVEF (from 27.5 1.6% to 35.1 2.4% [P=0.004, n=8] and 41.2 4.5% [P=0.013, n=5] at 4 and 12 months after CSC infusion, respectively) and regional EF in the CSC-infused territory. Infarct size (late gadolinium enhancement) decreased after CSC infusion (by manual delineation: -6.9 1.5 g [-22.7%] at 4 months [P=0.002, n=9] and -9.8 3.5 g [-30.2%] at 12 months [P=0.039, n=6]). LV nonviable mass decreased even more (-11.9 2.5 g [-49.7%] at 4 months [P=0.001] and -14.7 3.9 g [-58.6%] at 12 months [P=0.013]), whereas LV viable mass increased (+11.6 5.1 g at 4 months after CSC infusion [P=0.055] and +31.5 11.0 g at 12 months [P=0.035]).

Isolation of CSCs from cardiac tissue obtained in the operating room is feasible and does not alter practices during CABG surgery. CMR shows that CSC infusion produces a striking improvement in both global and regional LV function, a reduction in infarct size, and an increase in viable tissue that persist at least 1 year and are consistent with cardiac regeneration.

This study is registered with clinicaltrials.gov, trial number NCT00474461.

Visit link:
Administration of cardiac stem cells in patients with ischemic ...

Recommendation and review posted by Bethany Smith

Stem cells are the building blocks of your skin. They have a unique ability to replace damaged and diseased cells. As they divide, they can proliferate for long periods into millions of new skin cells.

As we age, our stem cells lose their potency. Your skins ability to repair itself just isnt what it used to be. The result can be fine lines, wrinkles, age spots, and sagging skin. But non-embryonic stem cells the same stem cells active early in life are highly potent.

Emerge Skin Cares Anti-Aging Stem Cell Skin Care Serum tap into the potency of these stem cells to renew skin.

Scientists at Emerge Labs Stem Cell Skin Care discovered that human non-embryonic stem cell extracts can renew skin by replacing old cells with healthy new ones. These stem cell extracts stimulate your own skins abilities to repair itself. And Emerge anti-aging stem cell serums were born. Where Stem Cells in Anti Aging Products Come From The first types of human stem cells to be studied by researchers were embryonic stem cells, donated from in vitro fertilization labs. But because creating embryonic stem cells involves the destruction of a fertilized human embryo, many people have ethical concerns about the use of such cells.

The non-embryonic stem cells in Lifeline stem cell serums are derived from unfertilized human oocytes (eggs) which are donated to ISCO from in vitro fertilization labs and clinics. Emerge Anti Aging Stem Cell Skin Care is Based On Proven Scientific Research Emerge Skin Cares exclusive anti-aging products are a combination of several discoveries and unique high-technology, patent-pending formulations.

PhytoCellTecMalus Domestica the first plant stem cell activefor skin stem cell protection with proven efficacy PhytoCellTec Malus Domestica is a liposomal preparation of apple stem cells developed by a novel, patent pending plant cell culture technology.

PhytoCellTec a novel plant cell culture technology has been invented to cultivate dedifferentiated callus cells from a rare Swiss apple. These apple stem cells are rich in epigenetic factors and metabolites, assuring the longevity of skin cells. PhytoCellTec Malus Domestica has been shown to protect skin stem cells and delay the senescence of hair follicles.

PhytoCellTec Malus Domestica provides a revolutionary anti-aging performance for real rejuvenation.

Claims with PhytoCellTec Malus Domestica Protects longevity of skin stem cells Delays senescence of essential cells Combats chronological aging

Go here to see the original:
Stem Cell Skin Care - Science Meets Beauty

Recommendation and review posted by Bethany Smith

stem cell therapy treatment for dystonic cerebral palsy by dr alok sharma, mumbai, india
improvement seen in just 3 months after stem cell therapy treatment for dystonic cerebral palsy by dr alok sharma, mumbai, india. Stem Cell Therapy done date...

By: Neurogen Brain and Spine Institute

View post:
stem cell therapy treatment for dystonic cerebral palsy by dr alok sharma, mumbai, india - Video

Recommendation and review posted by Bethany Smith

O.M.D. - Genetic Engineering

By: Countdown Chart History

See the article here:
O.M.D. - Genetic Engineering - Video

Recommendation and review posted by Bethany Smith

Bridge To The Soul
Art 4 All People in collaboration with USC present: Bridge To The Soul/The Art Of Healing art exhibition curated by the transformative arts organization, Art...

By: Beatriz Eugenia

Go here to read the rest:
Bridge To The Soul - Video

Recommendation and review posted by Bethany Smith

stem cell therapy treatment for Cerebral Palsy with Hemiplegia by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for cerebral palsy with hemiplegia by dr alok sharma, mumbai, india. Stem Cell Therapy done...

By: Neurogen Brain and Spine Institute

Read more:
stem cell therapy treatment for Cerebral Palsy with Hemiplegia by dr alok sharma, mumbai, india - Video

Recommendation and review posted by simmons

Kosair Charities gift helps UofL spinal cord injury research
Efforts by University of Louisville researchers to help children with spinal cord injuries received a significant boost today. UofL announced that Kosair Cha...

By: University of Louisville

Read the original post:
Kosair Charities gift helps UofL spinal cord injury research - Video

Recommendation and review posted by sam

RIT Biomedical Engineering Co-op @ Wake Forest Institute of Regenerative Medicine
A fourth year biomedical engineering student, Katelyn Busse, explains her participation as a summer scholar for the Wake Forest Institute of Regenerative Medicine.

By: RIT BME

Read more:
RIT Biomedical Engineering Co-op @ Wake Forest Institute of Regenerative Medicine - Video

Recommendation and review posted by sam

The Promise of Stem Cells

Studying stem cells will help us understand how they transform into the dazzling array of specialized cells that make us what we are. Some of the most serious medical conditions, such as cancer and birth defects, are due to problems that occur somewhere in this process. A better understanding of normal cell development will allow us to understand and perhaps correct the errors that cause these medical conditions.

Another potential application of stem cells is making cells and tissues for medical therapies. Today, donated organs and tissues are often used to replace those that are diseased or destroyed. Unfortunately, the number of people needing a transplant far exceeds the number of organs available for transplantation. Pluripotent stem cells offer the possibility of a renewable source of replacement cells and tissues to treat a myriad of diseases, conditions, and disabilities including Parkinson's disease, amyotrophic lateral sclerosis, spinal cord injury, burns, heart disease, diabetes, and arthritis.

Scientists have been able to do experiments with human embryonic stem cells (hESC) since 1998, when a group led by Dr. James Thomson at the University of Wisconsin developed a technique to isolate and grow the cells. Although hESCs are thought to offer potential cures and therapies for many devastating diseases, research using them is still in its basic stages. hESCs are thought to offer potential cures and therapies for many devastating diseases, and we are now seeing the first clinical trials using cells derived from hESCs.

The NIH funded its first basic research study on hESCs in 2002. Since that time, biotechnology companies have built upon those basic foundations to begin developing stem cell-based human therapies. There are currently two active clinical trials using cells derived from human embryonic stem cells, both being conducted by a biotechnology company called ACT. The company has laboratories in Marlborough, Massachusetts and corporate offices in Santa Monica, California. ACT has begun enrolling patients for Phase I (safety and tolerability) clinical trials of two hESC-derived stem cell products:

In January, 2012, the investigators published a preliminary report on the first two patients treated with hESC-derived cells: http://www.ncbi.nlm.nih.gov/pubmed/22281388. A third patient was treated on April 20, 2012.

Late in 2007, scientists reported that they had been able to reprogram adult human skin cells to behave like hESCs. This type of stem cells is known as induced pluripotent stem cells, or iPSCs. Since these first reports, researchers have rapidly improved the techniques to generate iPSCs, creating a powerful new way to "de-differentiate" cells whose developmental fates were thought to be determined. In July 2013, Japans health minister approved the first clinical trial using cells derived from iPSCs. Masayo Takahashiin Kobe, Japan will use the cells to attempt to treat a form of blindness - age-related macular degeneration.

Bone marrow contains blood-forming stem cells (hematopoietic stem cells) that have been used for decades to treat blood cancers and other blood disorders. Umbilical cord blood is another source of hematopoietic stem cells that is being used in treatment. You can see a list of diseases that may currently be treated with hematopoietic stem cells at the website of the National Marrow Donor Program. You may also search for clinical trials testing "bone marrow stem cells" or "umbilical cord blood" on the ClinicalTrials.gov website.

A biotechnology company called Neuralstem (corporate headquarters in Rockville, Maryland) is conducting a clinical trial testing the use of human spinal cord stem cells to treat Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrigs Disease. The company obtained FDA approval to conduct a Phase I trial (safety and tolerability study) and began enrolling patients in January 2010. Twelve participants have received lumbar transplants, and in March 2012, the second participant received an injection in the cervial region. Details about this trial are listed on the ClinicalTrials.gov website.

Osiris Therapeutics (Columbia, Maryland) is conducting three different Phase 2 clinical trials with a product from adult mesenchymal cells (called Prochymal). The three trials are for:

Read more here:
Stem Cells and Diseases [Stem Cell Information]

Recommendation and review posted by Bethany Smith

The UCLA Program is a combined program caring for patients with Hematologic Malignancies receiving chemotherapy and those patients for whom Stem Cell Transplantation is the therapy of choice. The treatmentof blood and marrow cancers includecurrently available therapies, investigational drugs and treatments, as well as stem cell transplantation. Our physicians meet weekly to discussindividual treatment approachesas part of developing a coordinated treatment recommendation.

Bone Marrow Transplantation was first performed at UCLA in 1968 using a related allogeneic transplant to treat an 18 month old child with severe combined immunodeficiency syndrome. The UCLA Marrow Transplantation Program was formally initiated in 1973. Unrelated donor marrow transplants have been carried out at UCLA since 1987, and Cord Blood Transplants have been performed at UCLA since 1996. Autologous transplants have been performed at our program since 1977. Since 1992 most of the Autologous Transplants have utilized Peripheral Blood Stem Cells. Since 1998 an increasing number of the Allogenic Transplants have utilized Peripheral Blood Stem Cells. From inception to the completion of 2007 we have performed 3726 transplants (3080 transplants in the adult population and 646 in the pediatric population).

For decades, this comprehensive program has provided a full range of services as a local, regional, national, and international referral center for transplantations for selected malignancies:

Our goals include finding new and innovative treatments for malignancies and expanding the effectiveness and applicability of bone marrow transplantation through such means as biologic response modifiers, growth factors, and chemotherapeutic agents.

Protocols involving chemotherapy with or without radiation therapy for patients in remission or relapse are available using bone marrow or peripheral blood stem cells from allogeneic, autologous and unrelated donors.

A bone marrow transplant is a procedure that transplant healthy bone marrow into a patient whose bone marrow is not working properly. A bone marrow transplant may be done for several conditions including hereditary blood diseases, hereditary metabolic diseases, hereditary immune deficiencies, and various forms of cancer.

Visit our Health Library to learn more:

Bone MarrowTransplant

How to Schedule Your Evaluation Appointment at UCLA

The United Network for Organ Sharing (UNOS) provides a toll-free patient services lines to help transplant candidates, recipients, and family members understand organ allocation practices and transplantation data. You may also call this number to discuss problems you may be experiencing with your transplant center or the transplantation system in general. The toll-free patient services line number is 1-888-894-6361

Go here to read the rest:
Bone Marrow/Stem Cell Transplant | UCLA Transplantation Services ...

Recommendation and review posted by Bethany Smith

A bone marrow transplant is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells.

Bone marrow is the soft, fatty tissue inside your bones. Stem cells are immature cells in the bone marrow that give rise to all of your blood cells.

There are three kinds of bone marrow transplants:

Before the transplant, chemotherapy, radiation, or both may be given. This may be done in two ways:

A stem cell transplant is done after chemotherapy and radiation is complete. The stem cells are delivered into your bloodstream usually through a tube called a central venous catheter. The process is similar to getting a blood transfusion. The stem cells travel through the blood into the bone marrow. Most times, no surgery is needed.

Donor stem cells can be collected in two ways:

A bone marrow transplant replaces bone marrow that either is not working properly or has been destroyed (ablated) by chemotherapy or radiation.

Your doctor may recommend a bone marrow transplant if you have:

A bone marrow transplant may cause the following symptoms:

Possible complications of a bone marrow transplant depend on many things, including:

See the original post here:
Bone marrow transplant: MedlinePlus Medical Encyclopedia

Recommendation and review posted by Bethany Smith

Stem Cell Stories trailer - Stem Cell Therapy Europe
Stem Cell Stories trailer - Stem Cell Therapy Europe.

By: stemcelltherapy.eu

See original here:
Stem Cell Stories trailer - Stem Cell Therapy Europe - Video

Recommendation and review posted by Bethany Smith

(201) 677-CELL

GMP Manufacturing

Product Development

Cell & Tissue Processing

Storage & Distribution

Consulting & Regulatory

At PCT, we're all about you, our Client. We're committed to cell therapy, our Clients, and their success. PCT is an industry leader in contract development and manufacturing of cell therapy products. With over 12 years of exclusive cell therapy-focused experience, we help our Clients bridge the gap between discovery and patient care through efficient transfer of cell-based therapies from laboratory into clinical practice. In all Client partnerships we place paramount importance on product quality, technical and operational excellence, exceptional customer service, and the protection of Client's proprietary information. We're here to make sure your dream manifests in the real world.LEARN MORE

PCT is dedicated to bridging the gap between the concepts in the cell therapy industry and their therapeutic application in patient care by providing our Clients with the maximum quality and value services in support of their cell therapy product and technology commercialization efforts.

4 Pearl Court, Suite C Allendale, NJ 07401 (201) 883-5300

291 Bernardo Avenue Mountain View, CA 94043 (650) 964-6744

Read the original post:
Progenitor Cell Therapy | A NeoStem Company | Allendale, Mountain View

Recommendation and review posted by Bethany Smith

Overview of Gene Therapy for SMA

Updated September 20, 2013

Click here for a Drug Discovery Compass on Gene Therapy.

Click here for a summary article from Genzyme on the status of SMA Gene Therapy.

What is gene therapy? Gene Therapy is an approach to treating diseases by either modifying the expression of particular genes or by correcting abnormal genes. Gene therapy works by administration of DNA rather than a drug. Many different diseases are currently being investigated as candidates for gene therapy. These include cystic fibrosis, cardiovascular disease, AIDS, cancer and SMA.1

A gene that is inserted directly into a cell usually does not function. Instead, a carrier called a vector is genetically engineered to deliver the gene. Certain viruses are often used as vectors because they can deliver the new gene by infecting the cell. The viruses are modified so they cant cause disease when used in people. Viruses, such as adenoviruses, introduce their DNA into the cell. The gene therapy vector can be given systemically by IV or injected directly into a specific tissue in the body, where it is taken up by individual cells, like motor neurons in the case of SMA.

What has FSMA's role been in the project?-In 2010, FSMA awarded $100,000 to Dr. Brian Kaspar at Nationwide Childrens Hospital for SMA gene therapy development. Please click here to read the announcement. -In 2011, Dr. Brian Kaspar published a paper in "Molecular Therapy" on systemic gene delivery in large species with FSMA funding. Please click here to read the annoucement. -In 2012, FSMA awarded Dr. Kaspar $750,00 in drug discovery funding to advance a CNS delivered gene therapy for SMA. Please click here to read the announcement. -In 2013, NINDS awarded a $3,752,462 to Dr. Kaspar in collaboration with FSMA to advance a CNS-directed gene therapy to IND. Please click here to read the announcement.

How does gene therapy work in SMA? In the case of SMA, gene therapy could take several approaches. The most likely approach would be to replace the lost SMN1 gene in cells. A second approach could be to use small pieces of genetic material, called oligonucleotides, to improve the functioning of the back-up SMN2 gene. Please click here to read more about that approach. A third approach could be to use gene therapy to deliver neuroprotective proteins like growth factors to motor neurons to help keep them alive and well functioning.

The challenge with gene therapy for SMA is to find a way to deliver the genetic material to the spinal cord. A number of viruses are being studied for their ability to safely and effectively carrier the genetic material across the blood brain barrier, where they will be needed to treat a disease like SMA. In the past, these viruses could not cross the blood brain barrier. Recently one called AAV9 has been generated that reaches motor neurons very effectively. See figure below for details.

Figure 1. Gene therapy for mice with spinal muscular atrophy (SMA). SMA mice (null for the murine SMN gene and homozygous for variants of human SMN transgenes) are born with a normal motor neuron complement. However, the motor neurons undergo rapid attrition, likely a result of synaptic failure and denervation with attendant muscular atrophy. The mice become wasted and succumb at two weeks of age (left), analogous to an untreated mild human type I SMA. Injection of scAAV9-SMN into the facial vein of day-old SMA pups results in SMN expression in ~40% of motor neurons, normalization of synaptic electrophysiology and an extension of life span to >250 days, albeit at half the size of unaffected mice (right). Full results published in Foust, K.D. et al. Nat. Biotechnol. 28, 271274 (2010). This result has been replicated by multiple labs worldwide, including at Genzyme Corporation, the lab of Dr. Martine Barkats, and the lab of Dr. Mimoun Azzouz. Figure reprinted by permission from Macmillan Publishers Ltd: Nature Biotechnology, Mackenzie A., Genetic therapy for spinal muscular atrophy. Volume 28: 236-7. Copyright 2010.

Go here to see the original:
Spinal Muscular Atrophy Gene Therapy Research

Recommendation and review posted by Bethany Smith

Medical Educational Apps QVprep Lite Learn Genetic and genetic engineering app video part 6 7 8 9
QVprep Lite Genetic Engineering is FREE and has limited content. The app gives you the option to buy the paid QVprep Genetic Engineering app which has exhaus...

By: Deep Larry

See the original post here:
Medical Educational Apps QVprep Lite Learn Genetic and genetic engineering app video part 6 7 8 9 - Video

Recommendation and review posted by Bethany Smith

Medical Educational apps QVprep Lite Learn Genetics and Genetic Engineering app video part 10 11 1
QVprep Lite Genetic Engineering is FREE and has limited content. The app gives you the option to buy the paid QVprep Genetic Engineering app which has exhaus...

By: Deep Larry

Original post:
Medical Educational apps QVprep Lite Learn Genetics and Genetic Engineering app video part 10 11 1 - Video

Recommendation and review posted by Bethany Smith

Medical Educational apps QVprep Learn genetics and Genetic Engineering app video part 13 14
QVprep Lite Genetic Engineering is FREE and has limited content. The app gives you the option to buy the paid QVprep Genetic Engineering app which has exhaus...

By: Deep Larry

Go here to see the original:
Medical Educational apps QVprep Learn genetics and Genetic Engineering app video part 13 14 - Video

Recommendation and review posted by Bethany Smith